Establishment of Subspecialized Care in Hematologic Malignancies and a Hematopoietic Cell Transplant Program

06/08/18
Issue
Citation

J Clin Pathways. 2017;3(3):45-48.

Reprinted J Clin Pathways. 2018;4(suppl 1):S35-S38.

Affiliation

1Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC

2Department of Pharmacy Services, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC

3Department of Infectious Diseases, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC

4Administration, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC

5Department of Cancer Biostatistics, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC

6Department of Cancer Pharmacology, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC

7Department of Solid Tumor Oncology, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC

Correspondence

Belinda R Avalos, MD

Department of Hematologic Oncology and Blood Disorders

1021 Morehead Medical Drive, Suite 3100

Charlotte, NC 28204

Phone: (980) 442-3100

E-mail: Belinda.avalos@carolinashealthcare.org

Disclosures

All researchers are employees of Levine Cancer Institute. Dr Bhutani reports honoraria from Amgen, Bristol-Myers Squibb, and Takeda. Dr Plesca reports an advisory board position with AstraZeneca. The other researchers report no relevant outside financial relationships.

Key Words